T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Clinical trial NCT02326974 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02326974
Sponsor: Dana-Farber Cancer Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HER-2 Positive Breast Cancer Breast Cancer Stage II Breast Cancer Stage III Breast Cancer

Start date: 2015-01-01
Primary completion: 2018-06-01
Enrollment: 164

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.